Morimoto T, Monden Y, Takashima S, Itoh S, Kimura T, Yamamoto H, Kitamura M, Inui K, Tanaka N, Nagano T
University of Tokushima, Japan.
Surg Today. 1994;24(3):210-4. doi: 10.1007/BF02032889.
A controlled cooperative study was carried out to assess the value of modified radical mastectomy for patients with stage II breast cancer. The data was analyzed from 11 institutions in the Shikoku District participating in a prospective clinical trial in which patients were randomly assigned either to a modified radical mastectomy group or an extended radical mastectomy group. These two groups of patients were similar to each other in terms of such background factors as age distribution, menopausal status, TNM classification, tumor size, location of the primary tumor, axillary nodal involvement, histological type, and estrogen receptor status. The median follow-up times in the modified and extended radical mastectomy groups were 4.7 and 4.5 years, respectively. The cumulative curves indicated no difference between the two groups in either disease-free survival or overall survival. The survival rates were classified according to the presence or absence of axillary nodal metastases. However, no significant difference was found between the two groups. These findings thus suggest that the routine removal of the grossly uninvolved major pectoral muscle and parasternal lymph nodes is not necessary in patients with stage II breast cancer.
开展了一项对照性合作研究，以评估改良根治性乳房切除术对II期乳腺癌患者的价值。分析了四国地区11家机构参与一项前瞻性临床试验的数据，在该试验中，患者被随机分配到改良根治性乳房切除术组或扩大根治性乳房切除术组。这两组患者在年龄分布、绝经状态、TNM分类、肿瘤大小、原发肿瘤位置、腋窝淋巴结受累情况、组织学类型和雌激素受体状态等背景因素方面彼此相似。改良根治性乳房切除术组和扩大根治性乳房切除术组的中位随访时间分别为4.7年和4.5年。累积曲线表明，两组在无病生存率或总生存率方面均无差异。生存率根据腋窝淋巴结转移情况进行分类。然而，两组之间未发现显著差异。因此，这些发现表明，对于II期乳腺癌患者，常规切除大体上未受累的胸大肌和胸骨旁淋巴结并非必要。
